Next Investors’ Post

For the first time, an AI-designed drug is heading into Phase II of clinical trials. This groundbreaking medication targets idiopathic pulmonary fibrosis, a debilitating lung disease.  Utilizing artificial intelligence, the drug was fast-tracked from discovery to Phase I trials in record time, showing promising results in reducing lung scarring. Now, with Phase II trials underway, we're one step closer to a potential breakthrough in treating this deadly condition. Stay tuned for updates! #AIDesignedDrug #MedTech #MedicalInnovation #HealthcareTechnology #DigiFacts

This exciting innovation works on the Tau portion of the disease rather than the existing treatments that focus on the external (to the neuron) amyloids

I want to clarify that recent blood tests claiming to indicate Alzheimer's disease do not directly lead to treatments for it or other similar diseases. The diagnostic focus remains on assessing the effects of the disease rather than addressing its underlying causes. It's crucial that we avoid the misleading narrative surrounding a mysterious protein as the sole culprit in these conditions. We've seen this kind of thinking before, notably in the 1990s, and it did not yield the breakthroughs hoped for. It’s the Genome! Comprehensive research into our genetic makeup is essential for uncovering the true origins of these diseases and developing effective treatments. Our development team have prioritized a scientifically sound approach to tackling these complex issues. #venturecapital #angelinvestor #cancer #hivaids  #bioOS #biotechnology #diagnostics #innovation #technology #management #startups #liquidbiopsy #neurodegenerativediseases #multiplesclerosis #parkinsonsdisease #alzheimersdisease #longhaulers #longcovid #humangenome #onetestonelife #longevity #artificialintelligence #rna #rnaseq #personalizedprevention

📢 Did you know that Alzheimer's disease may be transmissible in rare cases? 😮 Recent studies have found a link between Alzheimer's and a long-discontinued childhood medical procedure. Learn more about this fascinating discovery and its potential implications for our understanding of the disease. Check it out here: https://hubs.la/Q02jPjSQ0 #AlzheimersResearch #MedicalBreakthroughs

Join our expert faculty on September 16. Dive into the role of neuroinflammation as a therapeutic target in Alzheimer disease and highlight safety and efficacy data for investigational agents targeting neuroinflammation. Learn more: https://bit.ly/3w9PbV6 #ANA2024

Today is World Parkinson’s Day, a day to raise awareness and support those who live with Parkinson’s Disease (PD), a degenerative condition of the central nervous system. PD affects more than 10 million patients — and countless caregivers — around the world. It’s why Clario is committed every single day to helping our partners develop medicines that control symptoms or slow progression of the disease. Because the more we work together, the faster we can advance treatments for the people who need them most. Learn more about Clario’s approach to PD in clinical trials. Join our webinar on May 16, “A Holistic Approach to Parkinson’s Disease Endpoint Data Collection." Link: https://hubs.li/Q02sxKBK0 #WorldParkinsonsDay #ParkinsonsResearch #ClarioCares

Big advance in modern medicine!

This morning at the Alzheimer's Association® International Conference (AAIC) 2024 in Philadelphia, we presented data from a recent study that further demonstrates the high accuracy of our blood tests incorporating the ALZpath Inc. proprietary pTau217 antibody for Alzheimer’s disease diagnosis.   Our latest study, involving over 50,000 samples from 40 cohort studies, highlights the precision of the pTau217 antibody in determining amyloid burden across all stages of Alzheimer’s disease progression. This supports early detection, treatment, and tracking.   "The need for accurate and convenient testing methods, such as blood tests, has never been more evident," says Chad Holland, CEO of ALZpath. Our pTau217 antibody is a game-changer, offering a less invasive and more accessible alternative to traditional diagnostic methods. Read the full press release here: https://lnkd.in/gFjhVS3C   To learn more about ALZpath and our innovative solutions, visit https://alzpath.bio/ and follow us here on LinkedIn for the latest updates.   #Alzheimers #AlzheimersResearch #AAIC2024 #HealthcareInnovation #BloodTests #EarlyDetection #pTau217

#Exosome research is soaring with the potential to transform disease treatment. This boom is driven by the alarming rise in chronic disease, strides in exosome technology, and the increase in clinical studies targeting exosome-based research, according to BNN Breaking. We are providing the groundbreaking tools needed to advance #exosomeresearch with our ExoVerita Pro Platform. "With each breakthrough, we edge closer to a future where the management of chronic diseases is not just a vision, but a tangible reality, heralding a new dawn in medical science." - bnn Read the article> https://lnkd.in/gzTxpfKk #liquidbiopsy #precisionmedicine #healthcare

Revised Stage Group Definitions: Stage IIB: Previously defined as T3N0M0, this stage has been reclassified to T1-T2N1M0. This change reflects a more accurate representation of prognosis where tumor size and nodal status are considered more comprehensively. Stage IIIA: Updated from T1-T2N1M0 to T3N0-N1M0, adjusting the classification to better correlate with survival outcomes. Stage IIIC: Modified from T3-T4N1M0 to T4N1M0, narrowing the criteria to ensure that the classification more closely aligns with the prognosis observed in patient populations. Elimination of Stage 0: Stage 0, which represented in situ disease or high-grade squamous intraepithelial lesions (HSIL) and was not an invasive malignancy, has been removed. This adjustment prevents the over-treatment of pre-malignant conditions and aligns treatment protocols more closely with clinical significance.